Company name: Biobeat Website: <a href="https://www.bio-beat.com/">https://www.bio-beat.com/</a>

CEO name: Arik Ben Ishay Cell (Tomer Epstein)

CATEGORY: Digital Health

SESSION: Hospital at home: universities 'and hospitals' innovations

o Executive Summary / Investment Rational Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths.

Biobeat solutions provides an exceptional tool in Cardiovascular space and Hypertension management, transforming the current way of blood pressure management by eliminating the cuff, providing high patient adherence and satisfaction with additional analytics and insights.

o Core Technology What is the technology, its uniqueness, and its value proposition?

Biobeat developed a sensor incorporated in a chest patch and watch factors, enable to obtain over 10 vital signs including: blood pressure, heart rate, SPO2, respiratory rate, temperature and more. Solution obtains FDA, CE, TGA and other regulatory approvals. Currently this is the only solution with such wide range of regulatory approved vital signs.

o Product Profile/Pipeline Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships.

Biobeat has succeeded in forging over 10 distribution agreements including in Europe, LATAM and Asia. Including agreements with top tier hospitals in the US including Mayo, Ochsner, Carilion, OSF and more. Increasing sales and global outreach steadily over time and scaling the usage of the Biobeat solution.

o Business Strategy Briefly describe how the company will apply its core technology, generate short-term and long-term revenues.

The Biobeat solution promotes cost savings and resource allocations by eliminating the tedious work of vital sign collection, carving out approximately 90 minutes per day per staff. The solution also promotes patient transition from high acuity wards such as ICU to gen ward and from gen ward to the patient home, all by removing remaining the same level of care and observation.

o What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans Global market expansion and deepening the usage in the US for ABPM, in patient monitoring and hospital at home.